Certara, Inc. Stock Price, News & Analysis

Certara, Inc. (Nasdaq: CERT) has announced the pricing of its underwritten public offering of 10 million shares of common stock by existing stockholders at $25.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,500,000 shares. Certara will not receive any proceeds from this offering. The closing is anticipated around March 29, 2021, subject to customary conditions. The offering is managed by Jefferies, Morgan Stanley, and BofA Securities.

Certara, Inc. announced a proposed underwritten public offering of 17 million shares of its common stock by selling stockholders, with an additional 2,550,000 shares available for purchase by underwriters. Certara will not receive proceeds from this offering. The underwriting team includes Jefferies, Morgan Stanley, and BofA Securities. A preliminary registration statement has been filed with the SEC but is not yet effective, meaning no sales can occur until it is approved. This initiative supports Certara's ongoing role in biosimulation technology for drug development.

Certara (Nasdaq: CERT) has licensed TrialAssure's ANONYMIZE software to enhance anonymization of clinical data. This collaboration allows Certara's regulatory science division, Synchrogenix, to offer tailored anonymization services as a SaaS model to over 1,650 global biopharmaceutical clients. The ANONYMIZE tool enables full configurability to sponsor specifications, leveraging machine learning for efficient data processing. This partnership aims to strengthen compliance with increasing regulatory demands for data transparency in clinical trials.

Certara, a leader in biosimulation, is set to join the Russell 1000® Index effective March 22, 2021. This inclusion is based on its strong financial performance and reflects the growing adoption of its biosimulation platform. The Russell 1000 Index tracks the 1,000 largest companies in the U.S., and membership can enhance visibility among institutional investors, with approximately $9 trillion in assets benchmarked to these indexes. Certara aims to leverage this milestone to increase stock awareness within the investment community.

Certara, a leader in biosimulation, reported its preliminary results for Q4 and the full year 2020. Q4 revenue reached $64.6 million, with a full-year total of $243.5 million, reflecting growths of 20% and 17% year-over-year, respectively. However, the company recorded a net loss of ($54.4 million) in Q4 and ($49.4 million) for the full year, an increase from previous losses. Adjusted EBITDA grew by 36% in Q4 and 28% for the year. Certara anticipates 2021 revenue between $272 million and $285 million.

Certara, Inc. (Nasdaq: CERT) reported that 2020 was the seventh consecutive year where 90% of new drug and biologic approvals by the FDA were by its customers. In total, the FDA approved 54 new medicines in 2020, many of which received orphan and breakthrough designations. Certara’s biosimulation platforms, including Simcyp™, Phoenix™, and GlobalSubmit™, have been pivotal for drug development, enabling the provision of drug label claims without extensive clinical studies. CEO William Feehery highlighted the company's role in transforming drug development through advanced modeling techniques.

Certara, Inc. (Nasdaq: CERT) will announce its preliminary financial results for Q4 and the full year of 2020 post-market on March 4, 2021. A conference call to discuss these results will take place at 5:00 p.m. ET, accessible to investors through specific dialing options and a live webcast. Certara specializes in biosimulation technologies for drug discovery and development, serving over 1,650 biopharmaceutical companies and regulatory agencies in 61 countries.

Certara, a leader in biosimulation, announced the launch of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator. This version includes new models for maternal health, virtual bioequivalence, and long-acting injectable drugs. The simulator has informed the FDA approval of over 75 drugs, enhancing clinical trial efficiency. The expanded Simcyp Biologics Simulator aids in predicting pharmacokinetics for biologic drugs, crucial for their development. This software is pivotal for optimizing drug safety and efficacy in a vibrant biopharmaceutical R&D landscape.

Certara, a global leader in biosimulation, announced the closing of its upsized IPO on December 15, 2020, selling 33,413,250 shares at $23.00 each, raising approximately $336.5 million. Out of this, Certara itself sold 14,630,000 shares while certain stockholders sold 18,783,250 shares. Shares started trading on Nasdaq under the ticker symbol 'CERT' on December 11, 2020. The underwriters included Jefferies, Morgan Stanley, and BofA Securities, among others. This offering was registered under an effective Form S-1 with the Securities and Exchange Commission.